Accessing BRCA1/2 data facilitates the detection of disease-associated variants, which is critical to informing clinical management of risks. BRCA1/2 data sharing is complex and many practices exist. We describe current BRCA1/2 data-sharing practices, in the United States and globally, and discuss obstacles and incentives to sharing, based on 28 interviews with personnel at U.S. and non-U.S. clinical laboratories and databases. Our examination of the BRCA1/2 data-sharing landscape demonstrates strong support for and robust sharing of BRCA1/2 data around the world, increasing global accesses to diverse data sets.
Get full access to this article
View all access options for this article.
References
1.
Y.Miki, J.Swenson, D.Shattuck-Eidens, and P.A.Futrealet al., “A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1,”Science266, no. 5182 (1994): 66-71, available at <https://doi.org/10.1126/science.7545954> (last visited January 16, 2019); R. Wooster, G. Bignell, J. Lancaster, and S. Swift et al., “Identification of the Breast Cancer Susceptibility Gene BRCA2,” Nature 378 (1995): 789-792, available at <https://doi.org/10.1038/378789a0> (last visited January 16, 2019); S.M. Domcheck and B.L. Weber, “Clinical Management of BRCA1 and BRCA2 Mutation Carriers,” Oncogene 25 (2006): 5825-5831, available at <https://doi.org/10.1038/sj.onc.1209881> (last visited January 16, 2019).
2.
J.Y.Cheon, J.Mozersky, and R.Cook-Deegan, “Variants of Uncertain Significance in BRCA: A Harbinger of Ethical and Policy Issues to Come?”Genetics in Medicine6, no. 12 (2014): 121, available at <https://doi.org/10.1186/s13073-014-0121-3> (last visited January 16, 2019).
3.
For more information on the impact of BRCA patents, see E.Van Zimmerman, D.Nicol, E.R.Gold, and J.Carbone, “The BRCA Patent Controversies: An International Review of Patent Disputes,” in S.Gibbon, G.Joseph, J.Mozerksy, A.zur Nieden, and S.Palfner, Eds., Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA (Oxford, UK and New York, NY: Routledge, 2014): at 151-174. See also S. Parthasarathy, Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Healthcare (Boston: MIT Press, 2007); S. Parthasarathy, Patent Politics: Life Forms, Markets, and the Public Interest in the United States and Europe (Chicago: The University of Chicago Press, 2017), J.M. Conley, R. Cook-Deegan, and G. Lãzaro-Muñoz, “Myriad after Myriad: The Proprietary Data Dilemma,” North Carolina Journal of Law and Technology 15, no.4 (2014): 597-637, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275833/> (last visited January 16, 2019).
4.
N.Hawkins, “The Impact of Human Gene Patents on Genetic Testing in the United Kingdom,”Genetics in Medicine13, no. 4 (2011): 320-324, available at <https://doi.org/10.1097/gim.0b013e3181fc50bc> (last visited January 16, 2019).
5.
See Association for Molecular Pathology v. Myriad Genetics Inc, 133 U.S. S. Ct. 2107 (2013).
6.
M.Landrum, J.M.Lee, M.Benson, and G.R.Brownet al., “ClinVar: Improving Access to Variant Interpretations and Supporting Evidence,”Nucleic Acids Research46, no. D1 (2017): D1062-1067, available at <https://doi.org/10.1093/nar/gkx1153> (last visited January 16, 2019).
7.
The Global Alliance for Genomics and Health, “A Federated Ecosystem for Sharing Genomic, Clinical Data,”Science352, no. 6291 (2016): 1278-1280, available at <https://doi.org/10.1126/science.aaf6162> (last visited January 16, 2019).
8.
G.C.Fernandes, R.A.D.Michelli, H.C.R.Galvão, and A. E.Paulaet al., “Prevalence of BRCA1/BRCA2 Mutations in a Brazilian Population Sample At-Risk for Hereditary Breast Cancer and Characterization of its Genetic Ancestry,”Onco-target7, no. 49 (2016): 80465-80481, available at <https://doi.org/10.18632/oncotarget.12610> (last visited January 16, 2019).
9.
M.Hall, J.Reid, M.Stat, and L.Burbridgeet al., “BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer,”Cancer115, no. 10 (2009): 2222-2233, available at <doi:10.1002/cncr.24200> (last visited January 16, 2019).
10.
K.Ready, A.M.Gutierrez-Barrera, C.Amos, and F.Meric-Bernstamet al., “Cancer Risk Management Decisions of Women with BRCA1 or BRCA2 Variants of Uncertain Significance,”Breast17, no. 2 (2011): 210-212, available at <https://doi.org/10.1111/j.1524-4741.2010.01055.x> (last visited January 16, 2019); A. E. Toland, A. Forman, F. Couch, and J.O. Culver et al., “Clinical Testing of BRCA1 and BRCA2: A Worldwide Snapshot of Technological Practices,” Genomic Medicine 3, no. 7 (2018), available at <https://doi.org/10.1038/s41525-018-0046-7> (last visited January 16, 2019); A. Kurian, K.Ward, A. Hamilton, and D. Deapen et al., “Uptake, Results and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer,” JAMA Oncology 4, no. 8 (2018): 1066-1072, available at <doi:10.1001/jamaoncol.2018.0644> (last visited January 16, 2019); J. Caswell-Jin, T. Gupta, E. Hall, and I. Petrovchich et al., “Racial/Ethnic Differences in Multi-Gene Sequencing Results for Hereditary Cancer Risk,” Genetics in Medicine 20, no. 2 (2018): 234-239, available at <doi:10.1038/gim.2017.96> (last visited January 16, 2019), T. Slavin, L. Van Tongeren, C. Behrendt, and I. Solomon et al., “Prospective Study of Caner Genetic Variants: Variation in Rate of Reclassification by Ancestry,” JNCI: Journal of the National Cancer Institute 110, no. 10 (2018): 1059-1066, available at <doi:10.1093/jcni/djy027> (last visited January 16, 2019).
11.
National Center for Biotechnology Information, “Tests,”GTR: Genetic Testing Registry, available at <https://www.ncbi.nlm.nih.gov/gtr/> (last visited January 16, 2019); National Center for Biotechnology Information, “Submitter's Page,” ClinVar, available at <https://www.ncbi.nlm.nih.gov/clinvar/submitters/> (last visited January 16, 2019).
12.
S.Richards, N.Aziz, S.Bale, and D.Bicket al., “Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendations of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,”Genetics in Medicine17, no. 5 (2015): 405-424, available at <https://doi.org/10.1038/gim.2015.30> (last visited January 16, 2019); G. Matthijs, E. Souche, A. Alders, and A. Corveleyn et al., “Guidelines for Diagnostic Next-Generation Sequencing,” European Journal of Human Genetics 24, no. 1 (2016): 2-5, available at <https://doi.org/10.1038/ejhg.2015.226> (last visited January 16, 2019).
13.
J.M.Bollinger, P.D.Zuk, M.A.Majumder, and E.Versalovicet al., “What Is a Medical Information Commons?”Journal of Law, Medicine & Ethics47, no. 1 (2019): 41-50.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
